NY-ESTÉE-LAUDER
11.3.2022 15:02:04 CET | Business Wire | Press release
Today, The Estée Lauder Companies Inc. (NYSE:EL)("ELC") announced key leadership appointments for its Travel Retail business, which follow the announcement that Olivier Bottrie, currently Global President, Travel Retail and Retail Development , will retire in June 2022 after an exceptional career.
The following appointments will be effective May 1, 2022:
- Israel Assa , currently President, Commercial, Travel Retail Worldwide , will succeed Olivier and will be named Global President, Travel Retail Worldwide . He will be based in New York and will report directly to Peter Jueptner, President, International. He will join the company’s Executive Leadership Team (ELT).
- Javier Simon , currently President, Travel Retail Asia Pacific , will succeed Israel, and will be named President, Commercial, Travel Retail Worldwide . He will report directly to Israel and will be based in Switzerland. He will join the company’s Executive Leadership Team (ELT).
- Andrea Dorigo, Senior Vice President, General Manager, Global Retail and Head of Commercial, North America, will continue to report directly to Mark Loomis, President, North America, for his Commercial, North America responsibilities, and will report directly to Peter for his Global Retail responsibilities.
“We are proud of the exceptional depth and quality of talent across the organization, and as Olivier steps into his well-deserved retirement, we are pleased to elevate Israel and Javier, two dynamic, internally-trained and highly experienced leaders into these roles of greater responsibility,” said Peter Jueptner. “ELC remains committed to investing in and growing our local and international talent around the world, particularly leaders like Israel and Javier, who have extensive first-hand experience in Travel Retail and deep global expertise across all aspects of prestige beauty.”
Please find further information about Israel’s and Javier’s respective appointments and Andrea’s updated matrix reporting line below.
Israel Assa Appointed Global President, Travel Retail Worldwide
With over 21 years of experience within The Estée Lauder Companies and Travel Retail, Israel Assa is renowned industry-wide as a passionate brand steward and brand builder who has continually championed innovation within the Travel Retail channel, making him uniquely qualified to lead ELC’s winning Travel Retail business.
In this role, Israel will lead The Estée Lauder Companies’ global Travel Retail business, which has grown from approximately 6% of ELC’s net sales in fiscal year 2004 to approximately 28% in fiscal year 2021.
Over the course of his career, Israel has held diverse roles across ELC’s Travel Retail business, touching all aspects of the channel as a Regional lead, a Brand lead and a Commercial lead. He has an intimate knowledge of how to bring together brands and retailers to develop locally-relevant consumer experiences, as well as scaling distribution to meet consumer demand.
In his most recent role as President, Commercial, Travel Retail Worldwide, Israel oversaw Travel Retail’s Regional businesses in APAC, EMEA, and Americas as well as created a centralized Center of Excellence in Switzerland to enhance the organization’s service to global and regional retailers. Since taking on this position in 2019, Israel has overseen tremendous growth within The Estée Lauder Companies’ Travel Retail business and has acted as a steadying force throughout the volatility of the global pandemic.
A change champion, under Israel’s leadership Travel Retail’s Regional organizations have focused on building new capabilities, simplifying processes, and investing in learning and technology to set up Travel Retail for sustainable, long-term success. This approach has paid off with ELC not only maintaining the top market share position during the pandemic1 , but the company is also well positioned to capture consumer spend when global international travel returns.
Israel joined The Estée Lauder Companies in New York in 2001 as Executive Director, Travel Retail Marketing, and moved to Miami as Vice President and General Manager, Travel Retail Americas, in July 2006. In 2014 Israel was appointed Senior Vice President and General Manager, Estée Lauder, Travel Retail Worldwide until taking on the role of Senior Vice President, Business Operations, Travel Retail Worldwide, in 2016.
A champion of the company’s values of Inclusion, Diversity, and Equity, Israel has played an active role in the creation of Travel Retail’s learning and development program with Florida A&M University, a top public Historically Black College/University (HBCU) in the United States,2 to build the next generation of Black beauty talent in Travel Retail. He is also a member of the advisory board for The Estée Lauder Companies’ Hispanic Connections employee resource group, that aims to strengthen the company's position within the Hispanic and Latino marketplace and community as well as focus on the professional growth of group members.
A Cuban American and a native New Yorker, Israel holds his Master of Business Administration from NYU and a Bachelor of Arts in International Studies from The University of Michigan, Ann Arbor. He also is a graduate of the Advanced Management Program of the Wharton School, University of Pennsylvania.
“Israel’s deep understanding of our Travel Retail business, his longstanding relationships with retailers and airport landlords, and his passion for our consumer make him perfectly positioned to take ELC’s Travel Retail business into its next generation of growth,” said Peter Jueptner. “I look forward to working closely with Israel to drive this business forward in his new position as Global President, Travel Retail Worldwide.”
Javier Simon Appointed President, Commercial, Travel Retail Worldwide
A well-respected, driven, and innovative leader with a track record of building high-performing teams, Javier’s deep understanding of the Travel Retail channel, strong retailer relationships and global experience make him extremely well-suited to step into the role of President, Commercial, Travel Retail Worldwide.
In this role, Javier will oversee Travel Retail’s Regional businesses in APAC, EMEA, and Americas as well as the global retailer Center of Excellence in Switzerland focused on commercial and channel partnerships.
Most recently appointed President, Travel Retail Asia Pacific, in 2019, Javier has been a transformational leader, overseeing a period of tremendous growth. Under his stewardship, powered by the traveling Chinese consumer, the rise in online pre-order and a commitment to delivering the highest quality brand-building experiences, Travel Retail Asia Pacific has continued to excel, even in the face of the global pandemic. Javier’s ability to steer his team through the uncertainties of the global pandemic, pivoting their focus to Hainan and Chinese domestic travel have been critical to maintaining success for the channel and the company.
Javier’s passion for innovating the retail experience and meeting the consumer wherever they are in the journey, has enabled The Estée Lauder Companies to lead the way in transforming the Travel Retail channel. In taking key strategic bets such as embracing the potential of online pre-order and diversifying the company’s consumer messaging to highlight experience as well as value, Javier and his team have proven Travel Retail’s ability to deliver an omnichannel, brand equity-building experience.
Javier has continually pushed the boundaries to grow ELC’s business and win within Travel Retail. His cultivation of the company’s brand portfolio, from launching new brands in the channel to scaling and developing brands to new heights, has been critical in sustaining Travel Retail’s top market share position. Taking his experience in Asia Pacific, his strong retailer relationships, and ability to build diverse teams of change agents, Javier is well positioned to scale the growth created in APAC across all three Travel Retail regions to capture the traveling consumer as international travel returns.
A native of Venezuela, Javier joined The Estée Lauder Companies in 2000 as Regional Director for the Estée Lauder brand in Travel Retail Americas, and then went on to become Vice President and General Manager for Travel Retail Americas in 2001. In 2006, Javier was appointed General Manager for the Swiss Affiliate before returning to Travel Retail as Vice President and General Manager, Travel Retail APAC, in 2009.
Javier holds his Bachelor of Science in International Studies from the Universidad Central de Venezuela and an MBA from the Ecole Supérieure de Commerce de Paris. He also is a graduate of the Advanced Management Program of the Wharton School, University of Pennsylvania.
“Javier is highly respected by his teams and peers within the industry as an innovative leader who creates a culture of excellence,” said Peter Jueptner. “His track record of growth, deep Travel Retail knowledge, and respect for the global consumer will be critical to continually capture and scale the future potential of Travel Retail. I look forward to his success in this role.”
Andrea Dorigo to Continue to Report Directly to Mark Loomis for Commercial, North America Responsibilities, and Directly to Peter Jueptner for Global Retail Responsibilities
Andrea’s new reporting line to directly to Peter for his Global Retail responsibilities reflects the elevation of the company’s Global Retail business to International to support its continued actions to lead retail transformation at the global level.
“I look forward to partnering closely with Andrea to drive retail growth in the brands and across the enterprise through innovative thinking and disruptive growth models,” said Peter Jueptner. “Together, we will further strengthen the vision and strategy for the future of retail at our company.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced and Dr. Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
__________________________
1
Generation Research 2019; Generation Research 2020
2
US News and World Report 2022 Best Colleges
View source version on businesswire.com: https://www.businesswire.com/news/home/20220311005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom